Midwestern home health and hospice provider ViaQuest is using the PGXL multi-drug diagnostic panel to add pharmacogenetic testing to their pain management program. Kathy Richard, ViaQuest’s chief clinical officer, describes the advantage:
“The current prescription method is guess work and often we are with patients who can’t communicate pain level. The genetic piece narrows it down for us to get the best dose.”
ViaQuest is tracking the effect a genetic understanding has on patient outcomes, and expects within three years to have data demonstrating the benefits of pharmacogenetics in pain management. Says Richard:
We hope that in the next 4 – 5 years, we are not the only hospice group doing this. The technology is available and a benefit to patients and families.